

Yun Dai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8275131/publications.pdf>

Version: 2024-02-01

137
papers

11,004
citations

61857

43
h-index

30848

102
g-index

138
all docs

138
docs citations

138
times ranked

20535
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
2	New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network. <i>Clinical Cancer Research</i> , 2010, 16, 376-383.	3.2	389
3	Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors. <i>Clinical Cancer Research</i> , 2004, 10, 3839-3852.	3.2	371
4	Mcl-1 Down-regulation Potentiates ABT-737 Lethality by Cooperatively Inducing Bak Activation and Bax Translocation. <i>Cancer Research</i> , 2007, 67, 782-791.	0.4	366
5	Blockade of Histone Deacetylase Inhibitor-Induced RelA/p65 Acetylation and NF- κ B Activation Potentiates Apoptosis in Leukemia Cells through a Process Mediated by Oxidative Damage, XIAP Downregulation, and c-Jun N-Terminal Kinase 1 Activation. <i>Molecular and Cellular Biology</i> , 2005, 25, 5429-5444.	1.1	237
6	Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights. , 2014, 143, 323-336.		219
7	A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2. <i>Journal of Biological Chemistry</i> , 2004, 279, 34227-34239.	1.6	217
8	Coadministration of Histone Deacetylase Inhibitors and Perifosine Synergistically Induces Apoptosis in Human Leukemia Cells through Akt and ERK1/2 Inactivation and the Generation of Ceramide and Reactive Oxygen Species. <i>Cancer Research</i> , 2005, 65, 2422-2432.	0.4	195
9	Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 1273-84.	1.9	181
10	The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells. <i>Cancer Research</i> , 2004, 64, 2590-2600.	0.4	141
11	Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF- κ B-dependent process. <i>Oncogene</i> , 2003, 22, 7108-7122.	2.6	136
12	Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-x _L , and Mcl-1. <i>Molecular and Cellular Biology</i> , 2009, 29, 6149-6169.	1.1	123
13	Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. <i>Blood</i> , 2004, 104, 509-518.	0.6	109
14	Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. <i>Cancer Research</i> , 2003, 63, 8420-7.	0.4	109
15	Interruption of the NF- κ B pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. <i>Blood</i> , 2004, 103, 2761-2770.	0.6	104
16	Targeting Multiple Arms of the Apoptotic Regulatory Machinery: Figure 1.. <i>Cancer Research</i> , 2007, 67, 2908-2911.	0.4	104
17	Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2015, 16, e25-e35.	1.1	100
18	Cyclin-dependent kinase inhibitors. <i>Current Opinion in Pharmacology</i> , 2003, 3, 362-370.	1.7	99

#	ARTICLE	IF	CITATIONS
19	Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. <i>Blood</i> , 2002, 100, 3333-3343.	0.6	96
20	Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. <i>Blood</i> , 2008, 112, 2439-2449.	0.6	91
21	Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells. <i>Clinical Cancer Research</i> , 2008, 14, 549-558.	3.2	86
22	A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. <i>Blood</i> , 2014, 124, 2687-2697.	0.6	82
23	CHK1 Inhibitors in Combination Chemotherapy: Thinking Beyond the Cell Cycle. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2011, 11, 133-140.	3.4	82
24	Cotreatment with Suberanoylanilide Hydroxamic Acid and 17-Allylamino 17-demethoxygeldanamycin Synergistically Induces Apoptosis in Bcr-Abl+Cells Sensitive and Resistant to STI571 (Imatinib Mesylate) in Association with Down-Regulation of Bcr-Abl, Abrogation of Signal Transducer and Activator of Transcription 5 Activity, and Bax Conformational Change. <i>Molecular Pharmacology</i> , 2005, 67, 1166-1176.	1.0	80
25	The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. <i>Cancer Research</i> , 2003, 63, 1822-33.	0.4	79
26	XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I κ B α and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. <i>Oncotarget</i> , 2016, 7, 78896-78909.	0.8	75
27	HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells <i>In Vitro</i> and <i>In Vivo</i>. <i>Clinical Cancer Research</i> , 2011, 17, 3219-3232.	3.2	72
28	Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. <i>Blood</i> , 2007, 109, 4415-4423.	0.6	66
29	Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. <i>Blood</i> , 2005, 105, 1706-1716.	0.6	65
30	Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation. <i>Clinical Cancer Research</i> , 2007, 13, 4280-4290.	3.2	63
31	Targeting SQSTM1/p62 Induces Cargo Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik. <i>Molecular and Cellular Biology</i> , 2014, 34, 3435-3449.	1.1	63
32	The NF (Nuclear factor)- κ B inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. <i>British Journal of Haematology</i> , 2010, 151, 70-83.	1.2	62
33	Synergism of ursolic acid derivative US597 with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual-targeting of apoptosis and glycolysis. <i>Scientific Reports</i> , 2014, 4, 5006.	1.6	62
34	Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. <i>Journal of Hematology and Oncology</i> , 2016, 9, 73.	6.9	62
35	Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. <i>Blood</i> , 2008, 112, 793-804.	0.6	61
36	Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF- κ B and Bim. <i>British Journal of Haematology</i> , 2011, 153, 222-235.	1.2	56

#	ARTICLE	IF	CITATIONS
37	Contribution of Disruption of the Nuclear Factor- κ B Pathway to Induction of Apoptosis in Human Leukemia Cells by Histone Deacetylase Inhibitors and Flavopiridol. <i>Molecular Pharmacology</i> , 2004, 66, 956-963.	1.0	54
38	Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents. <i>Current Oncology Reports</i> , 2004, 6, 123-130.	1.8	53
39	PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. <i>Cancer Biology and Therapy</i> , 2013, 14, 458-465.	1.5	53
40	The Histone Deacetylase Inhibitor Sodium Butyrate Interacts Synergistically with Phorbol Myristate Acetate (PMA) to Induce Mitochondrial Damage and Apoptosis in Human Myeloid Leukemia Cells through a Tumor Necrosis Factor- α -Mediated Process. <i>Experimental Cell Research</i> , 2002, 277, 31-47.	1.2	52
41	CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies. <i>Cancer Research</i> , 2012, 72, 4225-4237.	0.4	51
42	The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 878-889.	1.9	51
43	Inhibitors of MEK1/2 Interact with UCN-01 to Induce Apoptosis and Reduce Colony Formation in Mammary and Prostate Carcinoma Cells. <i>Cancer Biology and Therapy</i> , 2002, 1, 243-253.	1.5	45
44	BCL2L1/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance. <i>Autophagy</i> , 2015, 11, 416-418.	4.3	45
45	The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 1513-24.	1.9	45
46	Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: A novel synergistic therapeutic approach. <i>Experimental Hematology</i> , 2015, 43, 89-99.	0.2	44
47	MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. <i>Blood</i> , 2007, 110, 2092-2101.	0.6	43
48	Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. <i>Blood</i> , 2011, 118, 5189-5200.	0.6	42
49	The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. <i>Blood</i> , 2016, 127, 2219-2230.	0.6	42
50	A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax [®]). <i>Epigenomics</i> , 2012, 4, 571-589.	1.0	39
51	Histone Deacetylase Inhibitors and Rational Combination Therapies. <i>Advances in Cancer Research</i> , 2012, 116, 199-237.	1.9	39
52	High-density lipoprotein (HDL) promotes angiogenesis via S1P3-dependent VEGFR2 activation. <i>Angiogenesis</i> , 2018, 21, 381-394.	3.7	39
53	Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair. <i>Clinical Epigenetics</i> , 2019, 11, 137.	1.8	37
54	Resveratrol Sensitizes Acute Myelogenous Leukemia Cells to Histone Deacetylase Inhibitors through Reactive Oxygen Species-Mediated Activation of the Extrinsic Apoptotic Pathway. <i>Molecular Pharmacology</i> , 2012, 82, 1030-1041.	1.0	36

#	ARTICLE	IF	CITATIONS
55	Disruption of I κ B Kinase (IKK)-mediated RelA Serine 536 Phosphorylation Sensitizes Human Multiple Myeloma Cells to Histone Deacetylase (HDAC) Inhibitors. <i>Journal of Biological Chemistry</i> , 2011, 286, 34036-34050.	1.6	35
56	Enhancing CHK1 inhibitor lethality in glioblastoma. <i>Cancer Biology and Therapy</i> , 2012, 13, 379-388.	1.5	35
57	Detection of Urothelial Bladder Carcinoma via Microfluidic Immunoassay and Single-Cell DNA Copy-Number Alteration Analysis of Captured Urinary-Exfoliated Tumor Cells. <i>Cancer Research</i> , 2018, 78, 4073-4085.	0.4	34
58	Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients. <i>Molecular Cancer</i> , 2015, 14, 21.	7.9	33
59	Modulation of macrophages by a paeoniflorin-loaded hyaluronic acid-based hydrogel promotes diabetic wound healing. <i>Materials Today Bio</i> , 2021, 12, 100139.	2.6	32
60	An Intact NF-kappaB Pathway is Required for Histone Deacetylase Inhibitor Induced G1 Arrest and Maturation in U937 Human Myeloid Leukemia Cells. <i>Cell Cycle</i> , 2003, 2, 465-470.	1.3	31
61	Poly(ADP-ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Mammary Tumors. <i>Molecular Pharmacology</i> , 2012, 82, 322-332.	1.0	31
62	Characterization of IFN γ -producing natural killer cells induced by cytomegalovirus reactivation after haploidentical hematopoietic stem cell transplantation. <i>Oncotarget</i> , 2017, 8, 51-63.	0.8	31
63	The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01-Induced Apoptosis in Human Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2005, 11, 4589-4600.	3.2	30
64	Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. <i>Blood</i> , 2011, 117, 1947-1957.	0.6	29
65	Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells. <i>PLoS ONE</i> , 2014, 9, e89064.	1.1	27
66	Bryostatin 1 Increases 1- β -d-Arabinofuranosylcytosine-Induced Cytochrome c Release and Apoptosis in Human Leukemia Cells Ectopically Expressing Bcl-xL. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 301, 568-577.	1.3	26
67	Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737. <i>PLoS ONE</i> , 2014, 9, e103015.	1.1	26
68	Impairment of hypoxia-induced angiogenesis by LDL involves a HIF-centered signaling network linking inflammatory TNF α and angiogenic VEGF. <i>Aging</i> , 2019, 11, 328-349.	1.4	26
69	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Mitochondrial Dysfunction and Apoptosis Induced by 7-Hydroxystaurosporine and Mitogen-Activated Protein Kinase Kinase Inhibitors in Human Leukemia Cells That Ectopically Express Bcl-2 and Bcl-xL. <i>Molecular Pharmacology</i> , 2003, 64, 1402-1409.	1.0	25
70	ARNT/HIF-1 α links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma. <i>Cancer Medicine</i> , 2018, 7, 3899-3911.	1.3	25
71	Induction of Apoptosis in Human Leukemia Cells by the CDK1 Inhibitor. <i>Cell Cycle</i> , 2002, 1, 128-137.	1.3	23
72	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. <i>British Journal of Cancer</i> , 2018, 118, 388-397.	2.9	23

#	ARTICLE	IF	CITATIONS
73	Coadministration of UCN-01 with MEK1/2 Inhibitors Potently Induces Apoptosis in. <i>Cancer Biology and Therapy</i> , 2002, 1, 674-682.	1.5	22
74	Cyclin D1 Overexpression Increases the Susceptibility of Human U266 Myeloma Cells to CDK Inhibitors through a Process Involving p130-, p107- and E2F-Dependent S-Phase Entry. <i>Cell Cycle</i> , 2006, 5, 437-446.	1.3	21
75	Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. <i>Oncotarget</i> , 2017, 8, 59476-59491.	0.8	21
76	Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor re-growth. <i>Cancer Biology and Therapy</i> , 2005, 4, 1275-1284.	1.5	20
77	Identification of the histone lysine demethylase KDM4A/JMJD2A as a novel epigenetic target in M1 macrophage polarization induced by oxidized LDL. <i>Oncotarget</i> , 2017, 8, 114442-114456.	0.8	20
78	An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells. <i>Cell Cycle</i> , 2003, 2, 467-72.	1.3	20
79	Targeting Chk1 in the replicative stress response. <i>Cell Cycle</i> , 2010, 9, 1025-1030.	1.3	19
80	The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo. <i>Journal of Hematology and Oncology</i> , 2019, 12, 25.	6.9	19
81	Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 616-629.	1.9	18
82	High COX-2 expression contributes to a poor prognosis through the inhibition of chemotherapy-induced senescence in nasopharyngeal carcinoma. <i>International Journal of Oncology</i> , 2018, 53, 1138-1148.	1.4	18
83	The mechanisms and therapeutic targets of ferroptosis in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 965-986.	1.5	18
84	Loss of the BCL-2 Phosphorylation Loop Domain Is Required to Protect Human Myeloid Leukemia Cells from Flavopiridol-Mediated Mitochondrial Damage and Apoptosis. <i>Cancer Biology and Therapy</i> , 2002, 1, 136-144.	1.5	17
85	Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. <i>Cell Death and Disease</i> , 2020, 11, 778.	2.7	17
86	Cell cycle regulation and hematologic malignancies. <i>Blood Science</i> , 2019, 1, 34-43.	0.4	16
87	Diverse Epigenetic Regulations of Macrophages in Atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 868788.	1.1	16
88	Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death. <i>Cancer Biology and Therapy</i> , 2011, 12, 215-228.	1.5	15
89	LDL suppresses angiogenesis through disruption of the HIF pathway via NF- κ B inhibition which is reversed by the proteasome inhibitor BSc2118. <i>Oncotarget</i> , 2015, 6, 30251-30262.	0.8	15
90	The Role of Tyk2 in Regulation of Breast Cancer Growth. <i>Journal of Interferon and Cytokine Research</i> , 2011, 31, 671-677.	0.5	13

#	ARTICLE	IF	CITATIONS
91	Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A. <i>Cell Cycle</i> , 2002, 1, 143-52.	1.3	13
92	Dissecting the Roles of Checkpoint Kinase 1/CDC2 and Mitogen-Activated Protein Kinase Kinase 1/2/Extracellular Signal-Regulated Kinase 1/2 in Relation to 7-Hydroxystaurosporine-Induced Apoptosis in Human Multiple Myeloma Cells. <i>Molecular Pharmacology</i> , 2006, 70, 1965-1973.	1.0	12
93	LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism. <i>Leukemia Research</i> , 2012, 36, 491-498.	0.4	12
94	Decoding DNA methylation in epigenetics of multiple myeloma. <i>Blood Reviews</i> , 2022, 51, 100872.	2.8	12
95	IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF- κ B and caspase-8 dependent mechanisms. <i>Blood Advances</i> , 2021, 5, 3776-3788.	2.5	10
96	Targeting epigenetic modifiers to reprogramme macrophages in non-resolving inflammation-driven atherosclerosis. <i>European Heart Journal Open</i> , 2021, 1, .	0.9	9
97	Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1- β -D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis. <i>Biochemical Pharmacology</i> , 2003, 65, 1997-2008.	2.0	8
98	Methods to Study Cancer Therapeutic Drugs That Target Cell Cycle Checkpoints. <i>Methods in Molecular Biology</i> , 2011, 782, 257-304.	0.4	8
99	Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma. <i>Cancer Letters</i> , 2015, 366, 173-181.	3.2	7
100	Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1331-1339.	0.8	7
101	CDK inhibitor targets a hit or miss proposition?: Cyclin-dependent kinase inhibitors kill tumor cells by downregulation of antiapoptotic proteins. <i>Cancer Biology and Therapy</i> , 2006, 5, 171-173.	1.5	6
102	Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma. <i>Blood</i> , 2015, 126, 1818-1818.	0.6	5
103	The Lysine-Specific Demethylase KDM4A/JMJD2A Acts As a Tumor Suppressor in Multiple Myeloma. <i>Blood</i> , 2018, 132, 191-191.	0.6	4
104	Vorinostat Synergistically Potentiates MK-0457 Lethality in Chronic Myelogenous Leukemia (CML) Cells Sensitive and Resistant to Imatinib Mesylate.. <i>Blood</i> , 2007, 110, 1041-1041.	0.6	3
105	Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism.. <i>Blood</i> , 2009, 114, 297-297.	0.6	3
106	Nonlinear response surface in the study of interaction analysis of three combination drugs. <i>Biometrical Journal</i> , 2017, 59, 9-24.	0.6	2
107	The Rheumatoid Arthritis Drug Auranofin Has Significant in Vitro Activity in MCL and DLCL and Is Synergistic with a Glutathione Depleting Agent. <i>Blood</i> , 2012, 120, 1658-1658.	0.6	2
108	Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma. <i>Blood</i> , 2015, 126, 3048-3048.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Targeting the NF- κ B-Dependent HIF-1 α Pathway Reprograms Macrophage Polarization Induced By Oxidized LDL. <i>Blood</i> , 2017, 130, 993-993.	0.6	2
110	Novel mechanisms of action for immunomodulatory drugs (IMiDs) against multiple myeloma: from a tragedy to a therapy. <i>International Journal of Hematology & Therapy</i> , 2016, 2, 1-6.	0.1	2
111	Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 859455.	1.3	2
112	Abstract 3020: Targeting both canonical and non-canonical NF- κ B pathways by the IAP antagonist birinapant potentiates bortezomib anti-myeloma activity. <i>Cancer Research</i> , 2016, 76, 3020-3020.	0.4	1
113	Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma. <i>Blood</i> , 2014, 124, 2084-2084.	0.6	1
114	HDAC Inhibitors Reciprocally Interacts the Wee1 Inhibitor AZD1775 to Abrogate Both the G1/S and G2/M Checkpoints Via Chk1-Related cdc2/Cdk1 Threonine 14 Dephosphorylation in AML Cells. <i>Blood</i> , 2014, 124, 997-997.	0.6	1
115	CDK Inhibitors in Multiple Myeloma. , 2008, , 331-363.		1
116	Bortezomib Interacts Synergistically with Belinostat to Induce Apoptosis In Human Acute Myeloid and Lymphoid Leukemia Cells. <i>Blood</i> , 2010, 116, 3266-3266.	0.6	1
117	Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance. , 2011, , 171-195.		1
118	Bim-Targeting Therapy Circumvents Adaptive Bortezomib-Resistance In Myeloma Through a Novel Cross-Link Between Autophagy and Apoptosis. <i>Blood</i> , 2013, 122, 601-601.	0.6	1
119	A Multi-Center Epidemiological and Prognostic Analysis of Cytogenetic Abnormalities in a Cohort of 1015 Chinese Patients with Newly-Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 3094-3094.	0.6	1
120	107. <i>Cytokine</i> , 2014, 70, 53.	1.4	0
121	Abstract 5367: Simultaneous inhibition of Chk1 and MEK1/2 targets non-proliferating multiple myeloma cells. , 2011, , .		0
122	Abstract 2572: The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatinib mesylate (IM)-sensitive and -resistant CML and ALL cells in vitro and in vivo. , 2011, , .		0
123	Abstract 4667: Simultaneous Chk1 and MEK1/2 inhibition circumvents Mcl-1 anti-apoptotic function and bortezomib resistance in human multiple myeloma cells. , 2012, , .		0
124	Abstract 4706: Resveratrol potentiates the lethality of HDAC inhibitors in acute myelogenous leukemia cells. , 2012, , .		0
125	Targeting the Cell Cycle for Cancer Treatment and Neuroprotection. , 2013, , 591-654.		0
126	Abstract 3390: Simultaneous Chk1 and MEK1/2 inhibition circumvents Mcl-1-mediated anti-apoptotic functions and bortezomib resistance in human multiple myeloma cells. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
127	Abstract 3420: The novel Chk1 inhibitor MK8776 sensitizes AML cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.. , 2013, , .		0
128	Abstract 3346: A20/TNFAIP3, a novel target of histone deacetylase inhibitor-induced NF- κ B activation, functionally disables the extrinsic apoptotic pathway in human leukemia cells.. , 2013, , .		0
129	Abstract 1772: Overcoming drug-resistance in multiple myeloma by CRM1 inhibitor combination therapy. , 2014, , .		0
130	Abstract 4556: A therapeutic strategy combining the Wee1 inhibitor MK1775 with HDAC inhibitors targets both p53 wild-type or mutant AML cells. , 2014, , .		0
131	Abstract 4600: P-TEFb is a therapeutic target in human bortezomib-resistant multiple myeloma cells. , 2014, , .		0
132	Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism. Blood, 2014, 124, 4763-4763.	0.6	0
133	Abstract B15: Targeting SQSTM1/p62 induces cargo-loading failure and converts autophagy to apoptosis via NBK/Bik in human multiple myeloma cells.. , 2015, , .		0
134	Abstract LB-258: The NAE inhibitor pevonedistat (MLN4924) interacts with the HDAC inhibitor belinostat via disruption of the intra-S checkpoint and both HR and NHEJ DNA repair in AML cells. , 2015, , .		0
135	Clarithromycin Interacts with Lenalidomide in the Combination Regimen Bird and Overcomes Drug Resistance in Multiple Myeloma. Blood, 2016, 128, 2125-2125.	0.6	0
136	Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of I κ B α and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma. Blood, 2016, 128, 3299-3299.	0.6	0
137	IRF4 Is Reciprocally Dysregulated Via NF- κ B-Dependent Expression and Loss-of-Function Mutations in Multiple Myeloma. Blood, 2019, 134, 687-687.	0.6	0